# Takeda receives FDA approval to manufacture FLEXBUMIN at new Covington facility

Takeda Pharmaceutical Company received U.S. FDA approval for its new plasma manufacturing facility near Covington, Georgia to produce FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution. The facility had previously received FDA approval for GAMMAGARD LIQUID in June 2018.

- Type: Product launch
- Announced: 2019-03-18
- Where: Covington, Georgia, United States
- Status: completed
- Products: FLEXBUMIN 25% (Albumin (Human))
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Takeda Pharmaceutical](https://endata.com/companies/20775.md)

## Sources

- [biospace.com](https://www.biospace.com/takeda-receives-u-s-fda-approval-to-manufacture-flexbumin-at-new-plasma-manufacturing-facility-near-covington-georgia), 2019-03-18: "Takeda today announced that the United States Food and Drug Administration (FDA) has approved the company’s second submission for its new plasma manufacturing facility near Covington, Georgia for the production of FLEXBUMIN 25%."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.